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ABSTRACT
Introduction: Liver disease mortality and morbidity
are rapidly rising and liver transplantation is limited by
organ availability. Small scale human studies have
shown that stem cell therapy is safe and feasible and
has suggested clinical benefit. No published studies
have yet examined the effect of stem cell therapy in a
randomised controlled trial and evaluated the effect of
repeated therapy.
Methods and analysis: Patients with liver cirrhosis
will be randomised to one of three trial groups: group
1: Control group, Standard conservative management;
group 2 treatment: granulocyte colony-stimulating
factor (G-CSF; lenograstim) 15 µg/kg body weight daily
on days 1–5; group 3 treatment: G-CSF 15 µg/kg body
weight daily on days 1–5 followed by leukapheresis,
isolation and aliquoting of CD133+ cells. Patients will
receive an infusion of freshly isolated CD133+ cells
immediately and frozen doses at days 30 and 60 via
peripheral vein (0.2×106 cells/kg for each of the three
doses). Primary objective is to demonstrate an
improvement in the severity of liver disease over
3 months using either G-CSF alone or G-CSF followed
by repeated infusions of haematopoietic stem cells
compared with standard conservative management.
The trial is powered to answer two hypotheses of each
treatment compared to control but not powered to
detect smaller expected differences between the two
treatment groups. As such, the overall α=0.05 for the
trial is split equally between the two hypotheses.
Conventionally, to detect a relevant standardised effect
size of 0.8 point reduction in Model for End-stage Liver
Disease score using two-sided α=0.05(overall α=0.1
split equally between the two hypotheses) and 80%
power requires 27 participants to be randomised per
group (81 participants in total).
Ethics and dissemination: The trial is registered at
Current Controlled Trials on 18 November 2009
(ISRCTN number 91288089, EuDRACT number 2009-
010335-41). The findings of this trial will be
disseminated to patients and through peer-reviewed
publications and international presentations.
INTRODUCTION
Chronic liver disease is the ﬁfth commonest
cause of death in the UK whose incidence is
rising predominantly due to alcohol consump-
tion, obesity and hepatitis C virus infection.
At present liver transplantation is the only
curative treatment for end-stage liver disease
however this is limited by donor organ avail-
ability, the supply of which has not matched
the rising number of patients requiring liver
transplantation.1 2 Moreover, liver transplant-
ation requires long-term immunosuppression
which is associated with increased risk of car-
diovascular disease, renal impairment and
malignancy.3 There is a clear need for new
therapies for chronic liver disease which are
either an effective alternative to liver
Strengths and limitations of this study
▪ Large randomised controlled trial of haematopoi-
etic stem cells in patients with liver cirrhosis.
▪ Effects of granulocyte colony-stimulating factor
are tested in a separate arm from cell infusions.
▪ Patients study are well-defined (cirrhosis) within
narrow Model for End-stage Liver Disease scores
(11.50–15.49).
▪ Randomisation is stratified by disease aetiology
and recruitment site.
▪ Mixture of aetiologies of liver disease.
▪ No information on amount of haematopoietic
stem cells homing to the injured liver.
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transplantation or reduce the proportion of patients that
require transplantation.
Initial observations that the bone marrow may contrib-
ute to hepatic repair and regeneration4–6 were followed
by studies of the therapeutic beneﬁts of bone marrow
derived cells in animal models of liver injury. Bone
marrow (BM) cells injected into mice with chronic liver
injury resulted in a reduction in hepatic ﬁbrosis and an
improvement in serum albumin,7 while mobilisation of
BM cells by injection of GCSF reduced the severity of
liver injury and improved survival in both acute and
chronic models of liver injury.8 However, other studies
have shown either no beneﬁcial effect of BM cell injec-
tions9 or even a worsening of hepatic ﬁbrosis after bone
marrow cell injection.10
Despite varied outcomes in preclinical studies, mul-
tiple clinical studies of BM-derived stem cell therapy
have been performed. Am Esch and colleagues studied
patients without chronic liver disease undergoing liver
resection for metastatic cancer affecting the liver. They
demonstrated accelerated hepatic regeneration in
patients receiving infusions of BM-derived CD133+ stem
cells with concomitant portal vein embolisation prior to
hepatic resection.11–13 In patients with liver disease trials
of bone marrow stem cell therapy have included small
numbers of patients and have been designed to examine
safety and feasibility rather than efﬁcacy.3 14
The initial reports of the use of BM-derived stem cells
in patients with chronic liver disease utilised a variety of
approaches to the method of cell isolation and route of
delivery. Gordon et al15 administered GCSF to patients
with cirrhosis and collected CD34+ haematopoietic stem
cells (HSC) mobilised into the blood and infused them
directly into the liver via the hepatic artery. Alternatively,
investigators in another study directly harvested BM cells
from the iliac crest under general anaesthesia, selected
out mononuclear BM cells and infused these cells via the
portal vein.16 While both studies involved only small
numbers of patients, 5 and 9, respectively and lacked
control participants, they demonstrated that this form of
therapy appeared safe and feasible. Clinical outcomes
were reported in both studies and showed reduced serum
bilirubin and improved serum albumin 2 months follow-
ing cell infusion in the ﬁrst study15 and improved serum
albumin and Child-Pugh score (a marker of liver dysfunc-
tion) at 6 months in the second.16 These two initial
studies highlight the signiﬁcant number of variables
involved in comparing these and subsequent studies.
Further small-scale, uncontrolled studies have included
variations in the patients enrolled (aetiology and severity
of liver disease), the method of cell harvest (direct BM
aspiration or peripheral blood leukopharesis), the type
and number of cells infused (various populations from
unsorted mononuclear cells to puriﬁed CD133+ HSC)
and the route of cell infusion (hepatic artery, portal vein
or peripheral vein).3 The aim of many of these studies was
to determine safety and feasibility and in that sense the
outcomes were promising. However, the size and nature of
many of these subsequent studies meant that meaningful
conclusions on clinical outcomes could not be drawn.
In more recent small controlled trials, Lyra et al17
demonstrated signiﬁcant improvements in liver function
1 year following infusion of BM mononuclear cells into
the hepatic artery when compared with untreated control
patients.18 Ismail et al19 examined the role of infusion of
bone marrow mononuclear cells prior to liver resection in
patients with cirrhosis with hepatocellular carcinoma and
showed improved outcomes 3 months postoperatively com-
pared with patients undergoing resection alone.
There have been many reports of clinical studies
describing the use of BM stem cells and HSC in patients
with chronic liver disease, which have predominantly
involved small numbers of patients and made no compari-
sons with untreated controls. These studies were systemat-
ically reviewed by Moore et al20 and of the studies
considered only one21 was found to be of adequate trial
design to be informative regarding the potential efﬁcacy
of cell therapy and this trial was negative. The general
message from these studies is that stem cell therapy
appears to be a safe and feasible therapeutic option,
however its efﬁcacy has yet to be proven. There is a need
for larger, randomised, controlled studies of stem cell
therapy for liver disease with powered primary end points.
RESEARCH AIM
The REALISTIC trial will evaluate the efﬁcacy and safety
of CD133+ BM-derived HSC in patients with compen-
sated cirrhosis. The aim of the study is to demonstrate
an improvement in liver function and a reduction in
liver ﬁbrosis in patients receiving stem cell therapy com-
pared with those receiving standard management of
compensated cirrhosis.
METHODS AND ANALYSIS
The REALISTIC trial is a multicentre, early phase,
open-label randomised controlled trial of two different
therapies—(1) administration of G-CSF alone and (2)
administration of G-CSF, isolation of CD133+ BM HSC
followed by repeated infusion of CD133+ cells, compared
with standard management of compensated cirrhosis
according to local, national and international guidelines.
TRIAL ORGANISATION
The REALISTIC trial is an investigator led and designed
trial, co-ordinated by the Liver Research Group within the
Cancer Research Clinical Trials Unit at the University of
Birmingham. The University of Birmingham is the trial
sponsor and the trial is funded by the NIHR Biomedical
Research Unit for Liver Disease, Birmingham and the
Sir Jules Thorn Trust. The trial is run at three sites in the
UK (Birmingham, Edinburgh and Nottingham) and
recruitment began in May 2010.
The trial was registered at Current Controlled Trials
(http://www.controlled-trials.com) on 18 November
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2009 (ISRCTN number 91288089, EuDRACT number
2009-010335-41).
The procurement, processing, storage and distribution
of the Autologous CD133+ HSC is performed in
accordance with Tissue Quality and Safety Regulations
by establishments holding Human Tissue Authority
licences.
INCLUSION AND EXCLUSION CRITERIA
Patients eligible for the trial are those aged 18–70 with
compensated cirrhosis and a Model for End-stage Liver
Disease (MELD) score greater than or equal to 11.5 and
less than 15.5. The speciﬁc inclusion criteria are listed in
table 1.
In addition to the general exclusion criteria there are
speciﬁc exclusion criteria related to liver disease and to the
safety of GCSF administration, which are listed in table 2.
SCREENING AND RANDOMISATION
Patients will be identiﬁed and recruited at the participat-
ing trial site and give informed written consent at the
beginning of the screening visit prior to undergoing any
tests and procedures needed to assess eligibility.
Eligibility for the trial is determined by clinical assess-
ment including a full medical history and clinical exam-
ination, baseline blood tests, complete liver screen if not
previously completed as part of standard care, 12-lead
ECG, abdominal ultrasound sonography and liver stiff-
ness evaluation, baseline chronic liver disease question-
naire (CLDQ) and urinary pregnancy test in women of
childbearing age. As required by National Health
Service (NHS) Blood and Transplant Standard
Operating Procedures, prior to processing and storage
of cellular products, patients are tested for hepatitis B
virus (HBV), hepatitis C virus (HCV), HIV, human T-cell
lymphotropic virus 1 (HTLV1) and (HTLV 2) and
syphilis.
Eligible patients will be randomly assigned to one of
the three treatment groups on a 1:1:1 basis. To minimise
bias randomisation will be stratiﬁed by recruiting centre
and by aetiology of underlying liver disease (alcohol-
related liver disease, chronic HCV and other).
Table 1 Inclusion criteria
Criteria Details
Age 18–70
Cirrhosis Previous liver biopsy confirming histological features of cirrhosis
Transient elastography (Fibroscan) >18 kPa
Clinical and radiological features that in the opinion of the investigator are in keeping with a diagnosis of
cirrhosis
AST:Platelet Ratio Index (APRI) >2
Aetiology of Liver
Disease
Alcohol-related liver disease:
Features (clinical, biochemical, histological or radiological) of chronic liver disease with a compatible history
of alcohol excess (>80 g/day), in the absence of other causes of chronic liver disease
Abstinent for ≥6 months prior to enrolment
Chronic hepatitis C virus infection,
positive HCV Antibody +/− PCR positive for HCV RNA
Not currently on antiviral therapy
Chronic hepatitis B virus infection
Positive HBsAg and Anti-HBC
Established on antiviral therapy with adequate viral suppression
Primary biliary cirrhosis
Two out of: cholestatic LFTs, positive AMA (>1:40),compatible histology
If already receiving ursodeoxycholic acid: must be established on current dose >3 months prior to enrolment
Genetic haemochromatosis
Diagnosis made on basis of compatible biochemistry (transferrin sat >60%, ferritin >400), genotype
(homozygous C282Y or H63D, compound heterozygote) or Histology
Cryptogenic cirrhosis
Diagnosis of cirrhosis unattributable to any other cause
Non-alcoholic fatty liver disease
Either: histological evidence of steatosis in the absence of other liver diseases
Or: Imaging compatible with NAFLD (eg Fatty infiltration of liver) and one or more risk factors (eg, elevated
BMI, T2DM, hypertriglyceridaemia, hypertension)
And: The absence of significant alcohol consumption (<20 g/day) and no evidence of other causes of
chronic liver disease
α-1 anti-trypsin deficiency
Diagnosis based on compatible genetic, phenotypic or histological testing
MELD score 11.5–15.5
AMA, antimitochondrial antibody test; BMI, body mass index; HBC, hepatitis C virus; HBsAg, HBV surface antigen; T2DM, type 2 diabetes
mellitus; LFTs, liver function tests; MELD, Model for End-stage Liver Disease.
King A, et al. BMJ Open 2015;5:e007700. doi:10.1136/bmjopen-2015-007700 3
Open Access
group.bmj.com on November 26, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
STUDY TREATMENT
All patients will receive standard management for a
patient with compensated cirrhosis, which may include
disease speciﬁc medications (eg, ursodeoxycholic acid
for primary biliary cirrhosis) and treatments for the
complications of cirrhosis (eg β-blockers for prophylaxis
of variceal haemorrhage). Concomitant medications are
permitted at the discretion of the site investigator with
the exceptions of the introduction of antiviral therapy
for chronic HCV infection, changes to medications for
chronic HBV infection, the introduction of ursodeoxy-
cholic acid for primary biliary cirrhosis and participation
in another clinical trial of an investigational product.
Patients randomised to group 2 will begin treatment
within 7 days of randomisation and will receive subcuta-
neous injections of GCSF (lenograstim) 15 µg/kg body
weight daily for 5 days, in addition to standard
management.
Patients randomised to group 3 will begin treatment
within 7 days of randomisation and will receive subcuta-
neous injections of GSCF (lenograstim) 15 µg/kg body
weight daily for 5 days, in addition to standard manage-
ment. On the ﬁfth day of GCSF treatment leukapheresis
will be performed. Leukapheresis will be performed
according to the standard operating procedure in place
at each trial site and peripheral blood mononuclear
cells will be collected. If insufﬁcient peripheral blood
mononuclear cells are obtained then a second leuka-
pheresis will then be performed on day 6.
Isolation of CD133+ HSC from the harvested periph-
eral blood mononuclear cells is performed under
aseptic conditions within clean room facilities in accord-
ance with good manufacturing practice regulations
(Medicines and Healthcare products Regulatory Agency,
MHRA/HTA, UK). CD133+ HSC are isolated through
immunomagnetic positive selection using super para-
magnetic iron dextran particles directly conjugated to
CD133 antibodies. This is performed in a closed, sterile
system providing clinical grade enrichment (CliniMACS
Plus, Miltenyi Biotec, Germany). The CliniMACS system
has been shown to provide CD133+ cells at up to 97%
high purity and yields of up to 81%,22 23 with passive
depletion of unwanted cells. The CliniMACS Plus instru-
ment is CE-marked for clinical use in Europe.
Isolated CD133+ HSC are aliquoted in three portions
in the required quantities, one portion will be available
for immediate reinfusion and a further two portions will
be cryopreserved according to site standard protocols
for later reinfusion at day 30 and day 60 postrandomisa-
tion (ﬁgure 1). The dosage of CD133+ cells to be
re-infused is 0.2×106 cells/kg for each of the three infu-
sions at monthly intervals, thus requiring the collection
of a minimum of 0.6×106 cells/kg. This dosage is based
on maximising the number of cells to be re-infused
while ensuring that sufﬁcient cells can be harvested
from each patient to standardise the treatment. In the
event of there being insufﬁcient cells for three doses
then cells will be allocated preferentially to the ﬁrst,
Table 2 Exclusion criteria
Criteria Details
General Refusal or inability to give informed consent
Any situation that in the Investigator’s opinion may interfere with optimal study participation such as
alcohol or drug abuse, domicile too distant from study site, potential non-compliance or inability to
co-operate
Participation in any clinical study of an investigational agent within 30 days of randomisation
The presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, renal, metabolic,
haematological, neurological, psychiatric, systemic, ocular, gynaecological or any acute infectious
disease or signs of acute illness that in the opinion of the investigator might compromise the
patient’s safe participation in the study
Presence or history of cancer within past 5 years with exception of adequately treated localised
basal cell carcinoma of the skin, in situ cervical cancer or solid malignancy surgically excised in
total without recurrence for 5 years
Pregnancy or
Breastfeeding
Women of childbearing potential and men who have partners of childbearing potential who are not
willing to practise effective contraception for the duration of the study and for 12 months (females)
and 6 months (males) after the last study drug administration
Liver specific Alcohol ingestion >21 units/week (male) >14 units/week (female)
Aetiology of chronic liver disease out with those listed in the inclusion criteria
Ascites—unless minimal and well controlled with no changes to diuretic therapy in the last
3 months
Encephalopathy—current or requiring hospitalisation in last 3 months
Portal hypertensive bleeding—active or requiring hospitalisation in past 3 months
Hepatocellular carcinoma—current or previous
Liver transplantation—previous or on waiting list
GCSF related Recent history of pulmonary infiltrates or pneumonia: patients should have completely recovered
from any previous episodes, both clinically and radiologically
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then second and third dose. Levels of 1.2×106 cells/kg
were used as a cut-off in order to allow for 50% cell loss
during selection.
A recent study examining the effectiveness of periph-
eral blood stem cell mobilisation and harvesting in
patients with cirrhosis demonstrated that while this pro-
cedure was safe and effective, the number of cells har-
vested from cirrhotic patients was lower than in healthy
controls. As a mean number of 1.2±0.5×106 cells/kg were
collected in the Lorenzini study24 the target of 0.6×106
cells/kg in this trial should be achievable. CD133+ HSC
thawing and reinfusion is performed according to the
site standard protocol for the Reinfusion of Autologous
Stem Cells.
SAFETY CONSIDERATIONS
Prior studies have shown the safety and feasibility of
GCSF in the mobilisation of peripheral blood stem cells
in patients with cirrhosis and speciﬁc safety checks have
been included to provide further evaluation. An ultra-
sound scan to measure the spleen size will be performed
on day 5 of GCSF treatment as GCSF administration
increases spleen size but the signiﬁcance of this is not
clear in patients with cirrhosis and possible pre-existing
splenomegaly. The peripheral blood white cell count
will be measured on day 4 of GCSF treatment and treat-
ment discontinued if greater than 70×109 cells/mL.
A chest X-ray will be performed prior to administration
of GCSF to exclude pre-existing pulmonary inﬁltrates or
other lung diseases.
OUTCOME MEASURES
Primary outcome measure
The primary outcome measure will be change in
δ MELD score at 90 days from baseline (ﬁgure 2). The δ
MELD will be the difference between the MELD score
at baseline and day 90 with a positive δ MELD indicating
a worsening of the liver disease and a negative δ MELD
an improvement.
MELD was initially developed to determine risk of mor-
tality within 3 months in patients with cirrhosis undergoing
transjugular intrahepatic portosystemic shunt (TIPS) inser-
tion,25 but has subsequently been validated in outpatients
with compensated cirrhosis26 and across a broad spectrum
of liver disease.27 The MELD score is accurate in predicting
1 week, 3-month and 1 year mortality and is an independ-
ent predictor of clinical decompensation in patients with
compensated cirrhosis.28 MELD score is used by all the
major Western regulatory authorities involved in liver trans-
plantation (UK Transplant, Eurotransplant and UNOS) to
help prioritise the allocation of liver transplants.
Recent studies have shown that the change in MELD
score over time to be a better predictor of outcome than
the absolute or initial MELD score.29–31 In particular it has
been shown that at any MELD score the magnitude and
direction of change in MELD over the previous 30 days is
Figure 1 Outline of REALISTIC Trial. Patients are randomised to one of three arms as indicated in the flow chart.
King A, et al. BMJ Open 2015;5:e007700. doi:10.1136/bmjopen-2015-007700 5
Open Access
group.bmj.com on November 26, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
a signiﬁcant independent predictor of mortality.30 An
increasing MELD over 3 months is also associated with the
onset of hepatic decompensation in the form of variceal
bleeding, ascites and encephalopathy.31 32
The MELD score is thus a well-established prognostic
scoring system for assessing the severity of chronic liver
disease. MELD score is calculated using objective vari-
ables that are readily obtained namely serum bilirubin,
Figure 2 (1) For patients in groups 1 and 2 visit 1 and visit 2a should be combined into 1 day where possible. For patients in
group 3, timing of visit 2a will depend on scheduling of leukapheresis. (2) All screening tests must be completed less than 7 days
prior to randomisation and treatment and must start less than 7 days following randomisation. Day of randomisation will be
considered as day 1 for scheduling purposes. (3) Clinical assessment consists of complete history and examination at screening
and focused history and relevant examination at subsequent visits. (4) Vital signs to include heart rate, blood pressure,
temperature and weight. (5) Screening blood tests as detailed in section 5. (6) Standard blood tests consists of full blood count,
urea and electrolytes, liver function tests, magnesium and alanine aminotransferase (ALT) international normalised ratio (INR). (7)
Adverse effects and clinical events will be monitored continuously until completion of follow-up. Serious adverse events (SAE’s)
will be reported from the date of consent. All adverse events experienced by patients will be recorded irrespective of the causality
(see section 7). (8) Mandatory microbiological testing must be performed between 7 and 30 days prior to leukapheresis—HBV,
HCV, HIV, human T-lymphotrophic virus 1 and 2 (HTLV-1, HTLV-2) and syphilis. (9) The first re-infusion of CD133+ (group 3
patients only) will occur on one occasion only between days 6 and 10. The timing will be determined by the timing of each
patient’s leukopheresis. CD133+ cell isolation and the local hospital arrangements (see section 7.6 in the study protocol).
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serum creatinine and international normalised ratio
(INR). These results will be used to calculate MELD
scores using the accepted UNOS calculation, corrected
for UK units of measurement:26
MELD¼10½(0:957ln(Creat(mmol/L)0:011312217))
þ(0:378ln(Bil(mmol=L)0:058479532))
þ(1:12ln(INR))þ6:43:
The following standard caveats will apply:
Any value less than one will be given a value of 1.0
once converted to US units, to avoid a negative MELD
score.
If the patient has been dialysed twice in the past
7 days then the value for creatinine will be 4.0.
The maximum MELD score is 40; all values greater
than 40 are given a score of 40. (http://optn.
transplant.hrsa.gov/converge/resources/
MeldPeldCalculator).
SECONDARY OUTCOME MEASURES
The time points at which the following secondary
outcome measures will be recorded are shown in
ﬁgure 2.
Liver stiffness evaluation
Liver stiffness evaluation will be assessed by transient elas-
tography (Fibroscan, Echosens, France), a non-invasive
method for assessing liver ﬁbrosis. Mild amplitude and
low frequency vibrations (50 Hz) are transmitted to the
liver tissue, inducing an elastic shear wave that propagates
through the underlying liver tissue. The velocity of the
wave is directly related to tissue stiffness, considered as an
index of the amount of ﬁbrotic tissue. This is expressed
as a numerical value in kilopascals (kPa). The accuracy
and reproducibility of transient elastography has been
validated in chronic liver disease.33
Enhanced liver fibrosis test
This is a validated panel of highly sensitive ELISA assays
measuring matrix components and enzymes involved in
their turnover: hyaluronic acid, tissue inhibitor of matrix
metalloproteinase 1 and procollagen type III. The values
for each of these markers is combined in an algorithm
which produces a discriminant score (the ELF score)
related to the level of liver ﬁbrosis. The enhanced liver
ﬁbrosis (ELF) test (iQur, Southampton, UK) is accurate
in assessing liver ﬁbrosis in a range of chronic liver dis-
eases and is a sensitive, speciﬁc and reproducible
method for the non-invasive assessment of hepatic
ﬁbrosis.34
Chronic liver disease questionnaire
This is a liver-speciﬁc questionnaire for measuring
health-related quality of life in patients with chronic liver
disease. It includes 29 items divided into 6 quality of life
domains: abdominal symptoms, fatigue, systemic symp-
toms, activity, emotional function and worry. These
items are ranked on a 1–7 scale, providing a possible
range of scores from 29 (worst quality of life) to 203
(best quality of life). Validity has been demonstrated in
all forms of chronic liver disease and test–retest reliabil-
ity has been shown to be good.35 The chronic liver
disease questionnaire (CLDQ) is self-administered and
is designed to reﬂect the 2 weeks prior to testing.
Individual components of liver function
This will include bilirubin, albumin, INR and creatinine
values.
UK end-stage liver disease score
The UK end-stage Liver Disease (UKELD) score is a
scoring system developed by the UK Liver Transplant
Units to predict transplant waiting list mortality.36 The
score uses the parameters of bilirubin (Bil), INR, cre-
atinine (Creat) and sodium (Na) as follows:
UKELD¼ð5ðð1:079 lnINRÞþð0:297 lncreatinineÞ
þð0:626 lnbilirubinÞ
ð16:313 lnsodiumÞÞþ435Þ
INR, serum creatinine and bilirubin values less than 1
are capped at 1.
Serum creatinine values greater than 400 are capped
at 400.
Sodium values outside the range 112–150 are capped
at the lower (112) and upper (150) limits.
Circulating peripheral blood HSC
There are limited data on the effectiveness of
GCSF-induced stem cell mobilisation in patients with cir-
rhosis, so this trial will enable a more detailed assess-
ment of the safety and efﬁcacy of achieving this. The
numbers of circulating CD133+ HSC and circulating
CD34+ HSC in peripheral blood will be quantiﬁed by
ﬂow cytometry according to ISHAGE protocols.37
Clinical events and transplant-free survival
Liver-related clinical events will be recorded during the
12-month period of trial participation according to the
following criteria: ascites (new development of clinically
signiﬁcant ascites or the worsening of established
ascites), encephalopathy (requiring introduction of
treatment or hospitalisation), portal hypertensive bleed-
ing (conﬁrmed at endoscopic examination), spontan-
eous bacterial peritonitis (PMN cell count >250 cm3 in
ascitic ﬂuid), development of hepatorenal syndrome,
listing for liver transplantation, liver transplantation,
development of hepatocellular carcinoma or dysplastic
hepatic nodules and death. Transplant-free survival is
deﬁned as the interval between the date of randomisa-
tion and the date of transplant or death from any cause.
Surviving transplant-free patients will be censored at
date last seen alive.
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STATISTICAL ANALYSIS
Sample size justification
The primary outcome measure is the change in MELD
score from baseline to 90 days postrandomisation.
Analysis of 60 patients eligible for the trial in our clinic
cohort demonstrated a mean baseline MELD score of
13.5, with a mean change in MELD over 3 months of 0.0
±1.0. This indicates that no change in MELD over
90 days would be observed in conventionally treated
patients. A clinically signiﬁcant reduction would be at
least a 1 point reduction in MELD. The trial is designed
as a three-armed study with one control arm. The trial is
powered to answer two hypotheses of each treatment
compared to control but not powered to detect smaller
expected differences between the two treatment groups.
As such, the overall α=0.1 for the trial is split equally
between the two hypotheses. Conventionally, to detect a
relevant standardised effect size of 0.8 point reduction
in MELD score using two-sided α=0.05 (overall α=0.1
split equally between the two hypotheses) and 80%
power requires 27 participants to be randomised per
group (81 participants in total; 49). The null hypothesis
to be tested is that the change in mean at 90 days com-
pared across two groups (treatment vs control) is the
same. The alternative hypothesis is that the change in
mean at 90 days compared across two groups (treatment
vs control) is at least 0.8 SDs apart.
The number of participants lost to follow-up, or with-
drawn consent prior to initial treatment is expected to
be minimal. The Data Monitoring Committee (DMC)
may advise replacement of participants if numbers are
higher than anticipated.
ANALYSIS OF PRIMARY OUTCOME MEASURE
All analyses will be carried out on an intention-to-treat
basis, retaining participants in their randomised treat-
ment groups and including protocol violator and ineli-
gible participants, in order to maintain the unbiased
comparison of treatments created by the randomisation
procedure.
Baseline MELD score will be collected at randomisa-
tion and days 30, 60 and 90 postrandomisation. Change
in MELD will be calculated for each participant and
average changes presented and statistically compared for
each treatment group against control using 2-sample t
test or non-parametric two-sample Wilcoxon test if
appropriate.
Changes from baseline for secondary outcomes scored
as continuous measures will be calculated and presented
descriptively by treatment group. It is unknown over what
period the treatment remains active or if its effect
increases linearly or in some other way. As such the statis-
tical analysis plan will be updated to include an add-
itional coprimary ﬁnal analysis entailing a repeated
measures analysis over time, speciﬁcally a mixed effect
modelling procedure, taking into account the MELD
measurement captured at baseline, days 30, 60 and 90.
The introduction of mixed effects modelling will make
more efﬁcient use of the patient level information,
enhance the scope of the study to understand the trend
of treatment activity in more detail (rather than focusing
only at a speciﬁc time point, day 90) and address missing
values. To model the trend in MELD over time, a linear
mixed effects models (taking into account within subject
correlation) using linear, quadratic polynomials or more
ﬂexible semiparametric models will be considered.
Goodness of ﬁt tests will be used to compare the different
models. We will evaluate if MELD changes over time, and
if so, what is the pattern of change, as well as if the
pattern differs between the each treatment and control
group. For this analysis the null hypothesis to be tested is
that the slope of the change in MELD compared across
two groups (treatment vs control) is the same. The alter-
native hypothesis is that the slope of the change in MELD
compared across two groups differ.
The multilevel coprimary analyses detailed in the fore-
going await approval from the MHRA, as the REALISTIC
trials team have sought consent to amend the primary ana-
lyses in this manner and believe the proposed changes will
not be contested. The original powered analysis, the two
sample t test, remains part of the primary analyses.
DISCUSSION
There is a clear need for new therapies for chronic liver
disease as liver transplantation is limited by donor organ
availability and by long-term complications. It has been
proposed that BM-derived stem cell therapy may provide
a therapeutic option and evidence from preclinical
models has been encouraging.7 8 The small scale studies
performed in humans to date suggest the possibility of a
beneﬁcial effect in patients with liver disease but this has
not been robustly tested in randomised controlled
trials.3 The REALISTIC trial was designed to examine
the beneﬁts of repeated injections of bone marrow
derived CD133+ stem cells in patients with cirrhosis and
is the ﬁrst randomised controlled trial with a powered
primary end point to examine the safety and efﬁcacy of
repeated cell injections.
In the design of the trial a variety of experimental
approaches were considered, in particular the route by
which cell therapy would be administered and the
primary outcome measure by which the efﬁcacy of the
cell therapy would be determined.
Administration of cells directly into the vessels supplying
the liver (portal vein and hepatic artery) is invasive and
carries signiﬁcant risks, including bleeding and throm-
bosis. This approach had been used in initial studies
without complication, however, subsequent studies have
shown this to be complicated by portal hypertensive bleed-
ing following cell injection38 and one study was terminated
early following complications in two out of four patients
after hepatic artery injection.39 In this trial HSC will be
administered into a peripheral vein thus avoiding the
potential complications of repeated procedures to access
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hepatic vessels. In addition to reducing the risks of cell
injection, this approach has practical implications in
making the therapy more accessible and cost-effective as
specialised interventional radiological procedures are not
required.
In patients with compensated cirrhosis expected mor-
tality at 1 year is between 1% and 3% with median sur-
vival of 12 years, with complications of cirrhosis
developing at a rate of 5–7% per year.40 The low short-
term mortality in these patients means that utilising sur-
vival as the primary outcome measure would not be
appropriate. MELD score is an objective, prognostic
scoring system validated for patients with chronic liver
disease, and the variables required to calculate it are
easily obtained from standard blood tests. The magnitude
of change in MELD score is predictive of the develop-
ment of the complications of cirrhosis, and in this trial
the change in MELD score at 90 days will be used as the
primary outcome measure. The authors hope such a trial
design will ﬁll an important gap in the current literature
of cell therapy for liver disease. Furthermore such a
design may be a template for future studies with other
novel cell therapy products which are undergoing devel-
opment for the therapy of chronic liver disease.
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